Xarelto
Manufacturing · New Jersey, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
PO Box 200, Titusville, New Jersey, 0856...Website
www.xarelto-us.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Xarelto
XARELTO® is a medication that contains rivaroxaban, primarily used for the treatment and prevention of blood clots. The official patient website provides comprehensive prescribing and safety information, including important warnings. It is intended for patients who require anticoagulation therapy. The website serves as a resource for patients to understand their treatment options and safety considerations.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Xarelto your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Xarelto launches new products
Click to see if Xarelto had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Xarelto
Earning: See what the market has to say on Xarelto recently announced quarterly report
Website visits: Recent activity has been detected on your website
Xarelto, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Xarelto is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Xarelto has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Xarelto has new funding data
Recommended Actions
Reach out to Masked Content who joined Xarelto as Masked Content
Find 3 more new buyers
Compare Similar Companies to Xarelto
Compare insights from companies similar to Xarelto, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Xarelto
<$5M
1-10
Private
-
-
N/A
Company Profile Activity
Activity Insights
Xarelto is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Xarelto is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Xarelto.
Xarelto Tech Stack
A closer look at the technologies used by Xarelto
Xarelto News & Media
FDA Approves Two New Indications for XARELTO® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, N.J., Dec. 20, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved two pediatric indications for XARELTO® (rivaroxaban): the treatment of venous thromboembolism (VTE, or blood...XARELTO® (rivaroxaban) Helps Protect Pediatric Patients from Blood Clots in Late-Breaking Phase 3 EINSTEIN-Jr Study
RARITAN, N.J., July 8, 2019 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new results from the Phase 3 EINSTEIN-Jr study, showing pediatric patients (aged birth to 17 years) treated with XARELTO® (rivaroxaban) had a similar low risk of recurrent ...XARELTO® (rivaroxaban) Significantly Reduced Ischemic Stroke in Patients with Nonvalvular Atrial Fibrillation in Large, Real-World Meta-Analysis of Non-Vitamin K Antagonist Oral Anticoagulants (NOACs)
TITUSVILLE, N.J., March 11, 2019 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new results from a large, real-world meta-analysis of 95 studies investigating the use of non-vitamin K antagonist oral anticoagulants (NOACs), including XARELTO®...Janssen Submits Supplemental New Drug Application (sNDA) to FDA for XARELTO® (rivaroxaban) to Prevent Venous Thromboembolism (VTE) in Acute Medically Ill Patients
TITUSVILLE, N.J., Dec. 14, 2018 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a supplemental New Drug Application (sNDA) for XARELTO® (rivaroxaban) to the U.S. Food and Drug Administration (FDA) for the prevention of venous...
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Xarelto
Sign Up For FreeTo access detailed company insights
XARELTO® is a medication that contains rivaroxaban, primarily used for the treatment and prevention of blood clots. The official patient website provides comprehensive prescribing and safety information, including important warnings. It is intended for patients who require anticoagulation therapy. The website serves as a resource for patients to un... Read More
